Group 1 - The article highlights the focus on Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), particularly following its first quarter results and the approval of its drug candidate Rezdiffra as the first treatment for a specific condition [2] - The Biotech Forum community is actively discussing lucrative buy-write or covered call opportunities on selected biotech stocks, indicating a trend in investment strategies within the biotech sector [1] - The Biotech Forum offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions and weekly research updates, showcasing a collaborative investment approach [2] Group 2 - The article does not provide any specific financial data or performance metrics related to Madrigal Pharmaceuticals or the broader biotech industry [3][4]

Core Viewpoint - Madrigal Pharmaceuticals reported a narrower loss in Q1 2025 compared to the previous year and exceeded revenue expectations due to strong sales of its newly launched drug Rezdiffra for metabolic dysfunction-associated steatohepatitis (MASH) [1][2][3] Financial Performance - The company reported a loss of $3.32 per share, better than the Zacks Consensus Estimate of a loss of $3.62, and significantly improved from a loss of $7.38 per share in the same quarter last year [1] - Total revenues for the quarter reached $137.3 million, all from Rezdiffra sales, surpassing the Zacks Consensus Estimate of $114 million [2] - Research and development expenses decreased by 38% to $44.2 million due to reduced clinical study costs and changes in inventory accounting [4] - Selling, general and administrative expenses rose to $167.9 million from $80.8 million year-over-year, attributed to increased commercial activities for Rezdiffra [5] - As of March 31, 2024, the company had cash, cash equivalents, and marketable securities totaling $848.1 million, down from $931.3 million at the end of 2024 [5] Product and Market Updates - Rezdiffra received accelerated FDA approval in March 2024, becoming the first approved therapy for MASH, with over 17,000 patients currently receiving treatment [3] - Madrigal has submitted a regulatory filing in the EU for Rezdiffra, with a decision expected in mid-2025 [8] - Ongoing studies, including the pivotal phase III MAESTRO-NASH biopsy study, aim to provide long-term safety and efficacy data to support full approval of Rezdiffra [9][10] - Positive two-year data from the MAESTRO-NAFLD-1 study indicated a significant reduction in liver stiffness among treated patients, reinforcing the drug's potential benefits [11][12][13] Stock Performance - Year-to-date, Madrigal shares have increased by 8.2%, outperforming the industry, which has seen a decline of 2.2% [6]

Group 1 - Madrigal reported a quarterly loss of $3.32 per share, better than the Zacks Consensus Estimate of a loss of $3.62, and an improvement from a loss of $7.38 per share a year ago, representing an earnings surprise of 8.29% [1] - The company posted revenues of $137.25 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 20.35%, compared to zero revenues a year ago [2] - Madrigal shares have increased approximately 8.2% since the beginning of the year, while the S&P 500 has declined by 5.3% [3] Group 2 - The current consensus EPS estimate for the coming quarter is -$3.31 on revenues of $137.59 million, and -$12.43 on revenues of $576.53 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 23% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] Group 3 - The estimate revisions trend for Madrigal is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - For the three months ended March 31, 2025, the company recorded $137.3 million in product revenue, net, representing a 100% increase compared to the previous year[134]. - The cost of sales for the same period was $4.5 million, also reflecting a 100% increase due to the sales of Rezdiffra[135]. - Selling, general and administrative expenses increased by 108% to $167.9 million compared to $80.8 million in the previous year[133]. - The total operating expenses for the three months ended March 31, 2025, were $216.6 million, a 42% increase from $152.0 million in the same period last year[133]. - The net loss for the quarter was $73.2 million, a 50% improvement from a net loss of $147.5 million in the prior year[133]. Research and Development - Research and development expenses decreased by 38% to $44.2 million from $71.2 million in the prior year[133]. - Research and development expenses decreased to $44.2 million for the three months ended March 31, 2025, down 38% from $71.2 million in 2024[136]. - The company intends to selectively in-license or acquire rights to programs at all stages of development to diversify its portfolio and enhance its drug development capabilities[118]. Product Approval and Market Potential - The FDA approved Rezdiffra in March 2024, making it the first therapy for patients with MASH, and it became commercially available in April 2024[112]. - The company estimates approximately 1.5 million patients in the U.S. have been diagnosed with MASH, with about 525,000 having moderate to advanced fibrosis[115]. - The company plans to commercialize Rezdiffra in Europe, with a regulatory decision expected in mid-2025 and a potential launch starting in Germany in the second half of 2025[117]. Cash Flow and Financing - Cash, cash equivalents, restricted cash, and marketable securities totaled $848.1 million as of March 31, 2025, down from $931.3 million at the end of 2024, reflecting funding of operations[141]. - Net cash used in operating activities was $88.9 million in Q1 2025, a decrease of 40.3% from $149.2 million in Q1 2024[155]. - Net cash provided by investing activities was $163.9 million in Q1 2025, compared to $98.1 million in Q1 2024, primarily from sales and maturities of marketable securities[156]. - Net cash provided by financing activities was $8.6 million in Q1 2025, a significant drop from $573.7 million in Q1 2024, which included proceeds from a public offering[157]. - As of March 31, 2025, the outstanding principal under the Loan Facility was $115.0 million, with an interest rate of 9.95%[149]. - As of March 31, 2025, the company had drawn $115.0 million under the $250.0 million Loan Facility[160]. Future Outlook and Risks - The company anticipates continued significant losses until sufficient revenue is generated from Rezdiffra and other future products[142]. - The company has the ability to delay certain commercial and research activities due to liquidity concerns until those concerns are alleviated[142]. - There have been no material changes to market risks since December 31, 2024, and no near-term changes are anticipated[164]. - No significant changes to contractual obligations and commitments occurred during the three months ended March 31, 2025, compared to the previous fiscal year[163]. - The company received FDA approval for Rezdiffra in March 2024, with a tiered single-digit royalty payable to Roche on net sales[161]. - The company had approximately $89.1 million of obligations under agreements related to active pharmaceutical ingredients, expected to be paid through December 2027[162].

Madrigal Pharmaceuticals (MDGL) Q1 2025 Earnings Call May 01, 2025 08:00 AM ET Company Participants Tina Ventura - Chief Investor Relations OfficerBill Sibold - CEO & DirectorMardi Dier - CFOAndrea Newkirk - Biotechnolgy Equity ResearchAkash Tewari - Managing DirectorLiisa Bayko - Managing DirectorMayank Mamtani - Senior Managing DirectorEmma Gutstein - Equity Research Associate Conference Call Participants Eliana Merle - AnalystRitu Baral - MD & Senior Biotechnology AnalystYasmeen Rahimi - Sr. Research Ana ...

Madrigal Pharmaceuticals (MDGL) Q1 2025 Earnings Call May 01, 2025 08:00 AM ET Speaker0 Good day, and thank you for standing by. Welcome to Magical Pharmaceuticals First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. As a reminder, today's conference call is being recorded. I would now like to introduce Ms. Tina Ventura, Chief Investor Relations Officer. Please go ah ...

Exhibit 99.1 Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates CONSHOHOCKEN, Pa., May 1, 2025 – Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction- associated steatohepatitis (MASH), today reports first-quarter 2025 financial results and provides corporate updates. Bill Sibold, Chief Executive Officer of Madrigal, stated, "Since Rezdiffra's approval last year, we've e ...

First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress (May 7-10)Appointed David Soergel, M.D., to Chief Medical Officer; Rebecca Taub, M.D., named Senior Scientific and Medical Advisor Appointed Jacqualyn Fouse, Ph.D., to Board of DirectorsReports cash, cash equivalents, restricted cash and marketable securities ...

CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction- associated steatohepatitis (MASH), today announced six presentations at the upcoming European Association for the Study of the Liver (EASL) Congress, taking place from May 7-10, 2025, in Amsterdam, the Netherlands. Madrigal will share detailed two-year data from the open-label compensated MASH cirrhosis (F4c) arm ...

Core Viewpoint - Madrigal Pharmaceuticals is set to release its first-quarter 2025 financial results on May 1, 2025, before the U.S. markets open [1] Company Overview - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) focuses on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with significant unmet medical needs [3] - The company's primary medication, Rezdiffra (resmetirom), is a once-daily oral THR-β agonist targeting the underlying causes of MASH and is the first FDA-approved treatment for MASH with moderate to advanced fibrosis (F2 to F3 stages) [3] - An ongoing Phase 3 trial is assessing Rezdiffra for treating compensated MASH cirrhosis (F4c stage) [3] Upcoming Events - Following the financial results announcement, Madrigal's management will host a live webcast at 8 a.m. Eastern Time to discuss the financial and operational results [2] - The webcast will be accessible via the Investor Relations section of the Madrigal Pharmaceuticals website, with a recommendation for participants to register at least 15 minutes in advance [2]